Aurora Cannabis

Edmonton – October 15, 2026 -- Aurora Cannabis' board unanimously recommended that shareholders reject Curaleaf Holdings' revised hostile offer, which remains open until October 15, 2026, and said its special committee is actively exploring alternatives, including a deal with one or more third parties.

The recommendation, made on the unanimous advice of a special committee of independent directors, responds to the Notice of Variation, Change and Extension that Curaleaf filed on October 15, 2026. Aurora's financial advisor delivered an updated opinion concluding that the revised consideration is inadequate, from a financial point of view, to Aurora shareholders.

Board says revised offer shifts risk and cost onto Aurora shareholders

Aurora argues that the increase in consideration consists principally of Curaleaf shares at an inflated valuation. Aurora shareholders would therefore stay fully exposed to any decline in the Curaleaf share price.

Stamford, Conn. – – September 12, 2026 -- Curaleaf Holdings, Inc. released a fact sheet countering what it called inaccurate statements by Aurora Cannabis Inc. regarding Curaleaf's proposal to acquire the company, arguing its offer represents one of the highest premiums in a decade of Canadian M&A.

Curaleaf says its bid carries a 110% premium once Aurora's cash is excluded

Curaleaf's headline offer reflects a 45% premium, which the company says ranks among the higher Canadian M&A premiums of the past ten years. Stripping out cash on Aurora's balance sheet, Curaleaf calculates the effective premium at 110%. Curaleaf noted Aurora has continued issuing shares through an At-the-Market program at prices below the value implied by the offer, even after the bid was made public.